实用医学杂志 ›› 2022, Vol. 38 ›› Issue (23): 2903-2907.doi: 10.3969/j.issn.1006⁃5725.2022.23.003

• 临床新进展 • 上一篇    下一篇

儿童急性淋巴细胞白血病免疫治疗进展 

彭思静1 卢婕伦2 王子成1 曾晓珍3 邹亚伟1    

  1. 广州医科大学附属第一医院儿科(广州 510120);2 南方医科大学南方医院(广州510515); 3 南方医科大学顺德医院(广东佛山 528308)
  • 出版日期:2022-12-10 发布日期:2022-12-10
  • 通讯作者: 邹亚伟 E⁃mail:zywyhscg@qq.com
  • 基金资助:
    广东省自然科学基金项目(编号:2016A030313654)

A progress on immunotherapy for childhood acute lymphoblastic leukemia

PENG Sijing*,LU Jielun WANG Zicheng,ZENG Xiaozhen,ZOU Yawei.   

  1. Department of Pediatrics,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China

  • Online:2022-12-10 Published:2022-12-10
  • Contact: ZOU Yawei E⁃mail:zywyhscg@qq.com

摘要:

急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是儿童最常见的血液恶性肿瘤,近年来儿童 ALL 患者的预后有了显著改善。然而对于复发/难治 ALL 患者,常规的化学治疗缓解率低,预后不佳。随着免疫疗法的兴起,针对 ALL抗原相关的单克隆抗体和嵌合抗原受体T细胞等免疫治疗已被证实ALL有效,显著改善复发/难治ALL 患者的预后。

关键词:

急性淋巴细胞白血病, 免疫疗法, 儿童, 抗体, 嵌合抗原受体

Abstract:

Acute lymphoblastic leukemia(ALL)is the most common hematologic malignancy in children. The prognosis of ALL in pediatric patients has significantly improved in recent years. However,for pediatric popu⁃ lation with relapsed/refractory ALL,conventional chemotherapy has a low remission rate and provides no promising prognosis. With the emergence of immunotherapy,immunotherapies targeting ALL antigen ⁃associated monoclonal antibodies and chimeric antigen receptor T cells have shown to be effective against ALL,significantly improving the prognosis in patients with relapsed/refractory ALL. In this article,we review the immunotherapy for ALL in children.

Key words:

acute lymphoblastic leukemia, immunotherapy, children, antibody, chimeric antigen receptor